Research Roundup


Debbie Rigby covers the latest research relevant to pharmacists

Diagnosis and Management of Diabetes

The American Diabetes Association (ADA) published the 2016 Standards of Medical Care in Diabetes (Standards) to provide clinicians, patients, researchers, payers, and other interested parties with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. This synopsis focuses on eight key areas that are important to primary care providers, highlighting individualized care to manage the disease, prevent or delay complications, and improve outcomes.

Ann Intern Med. Published online 1 March 2016

 

Urinary incontinence in men: current and developing therapy options

Urgency incontinence in men presents as part of the overactive bladder (OAB) syndrome and can often coexist with benign prostatic obstruction (BPO). The pharmacotherapy options to treat OAB include antimuscarinics, β3 agonists and phosphodiesterase inhibitors. Antimuscarinics and β3 agonists are effective in treating OAB, and have been found to have no increased urinary retention risk in the group of patients with co-existing BPO.

Expert Opinion on Pharmacotherapy. Published online: 22 Jan 2016

 

Risk of venous thromboembolism in women taking the combined oral contraceptive

A systematic review and meta-analysis to assess VTE risk in women taking COCs, focusing on drospirenone, has concluded that there is no increased risk of VTE. The risk of VTE was increased in retrospective cohort and nested case control studies but not in case control and prospective cohort studies. The authors concluded that the difference in risk of VTE based on the choice of progestin in COCs is, at worst, very small in absolute terms.

Aust Fam Physician 2016;59:61-67.

 

Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes

For the majority of adults older than 65 years, the harms associated with glycosylated haemoglobin (HbA1c) target lower than 7.5% or higher than 9% are likely to outweigh the benefits. Optimal decisions need to be made collaboratively with patients, incorporating the likelihood of benefits and harms and patient preferences about treatment and treatment burden. For the majority of older adults, an HbA1c target between 7.5% and 9% will maximize benefits and minimize harms.

JAMA. 2016;315(10):1034-1045.

 

Previous CM sellers are 'irresponsible shopkeepers,' says UK expert
Next The latest AusPharmList posts

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.